1. ALLA AKTIER
  2. NYHETER
  3. LIPUM

Lipum

Nyheter Lipum Nyheter alla bolag

Lipum AB (publ) informs that Flerie Invest AB has passed the threshold for a mandatory bid

Lipum AB´s (publ) (“Lipum”) main owner Flerie Invest AB (“Flerie”) announced on 1 March 2024 that it has acquired an additional 859 shares in Lipum and that Flerie thereafter owns a total of 2,981,553 shares, corresponding to approximately 32.01 per cent of the total number of shares and votes in Lipum.

According to the Swedish Securities Council’s statement AMN 2023:30, Flerie was granted an exemption from the obligation to make a mandatory bid that could arise as a result of Flerie subscribing for its pro rata share in the rights issue that Lipum carried out in 2023. According to the exemption, an obligation to make a mandatory bid arises if Flerie subsequently acquires additional shares and thereby increases its voting rights in Lipum.

Thereby, the threshold for a mandatory bid according to the Takeover rules for certain trading platforms has been exceeded. According to Flerie’s press release, Flerie intends to revert with information about a possible public takeover bid for the remaining shares in Lipum within four weeks from 1 March 2024.

For further information, please refer to Flerie´s press release, Flerie Invest AB has increased its holding in Lipum AB (publ), whereby the limit for mandatory bidding has been exceeded – Flerie.

Contacts
Ola Sandborgh, CEO
ola.sandborgh@lipum.se
+46 72 218 80 21
Web: www.lipum.se

About Us
Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

Attachments
Lipum AB (publ) informs that Flerie Invest AB has passed the threshold for a mandatory bid

Datum 2024-03-04, kl 08:00
Källa MFN
Bifogade filer
Lipum AB (publ) informs that Flerie Invest AB has passed the threshold for a mandatory bid
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!